The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 15, 2011
Filed:
Oct. 25, 2005
Michael Firnges, Barsinghausen, DE;
Peter-colin Gregory, Hanover, DE;
Jochen Antel, Münder, DE;
Josephus Hubertus Maria Lange, Almere, NL;
Harald Waldeck, Isernhagen, DE;
Michael Firnges, Barsinghausen, DE;
Peter-Colin Gregory, Hanover, DE;
Jochen Antel, Münder, DE;
Josephus Hubertus Maria Lange, Almere, NL;
Harald Waldeck, Isernhagen, DE;
Abbott Products GmbH, Hanover, DE;
Abstract
Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one Kchannel opener as a first active agent and at least one CBcannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined Kchannel opening and CBantagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising Kchannel openers and CBantagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined Kchannel opening and CBantagonistic properties.